Notably, the PARP1 inhibitor talazoparib (BMN 673) elicited increased numbers of peritoneal CD8+ T cells and NK cells in an ovarian cancer mouse model and increased infiltration into ex vivo spheroids, in addition to increasing IFNγ and TNFα production levels62,63. This evidence concerns the gene IFNG and ovarian carcinoma.